clofazimine has been researched along with AIDS-Related Opportunistic Infections in 33 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 9.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 9.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined." | 9.07 | The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. ( Bartok, AE; Dubé, M; Haghighat, D; Havlir, D; Kemper, CA; Leedom, JM; Sison, JP; Tilles, JG; Yangco, B; Yao, Y, 1994) |
| " Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose." | 6.87 | Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. ( Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018) |
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 5.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 5.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "We conducted a randomized, open-label trial in 42 French hospitals to compare the clinical and bacteriologic efficacy of combination therapy with clarithromycin/clofazimine (Clm/Clof) with that of combination therapy with clarithromycin/rifabutin/ethambutol (Clm/Rib/Eth) as treatment for Mycobacterium avium bacteremia." | 5.08 | Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. ( Beuscart, C; Brel, F; Dautzenberg, B; Doco-Lecompte, T; Grosset, J; May, T; Perronne, C; Saint-Marc, T; Vincent, V, 1997) |
| " a placebo, each in combination with clofazimine and ethambutol, for the treatment of MAC bacteremia." | 5.07 | Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. ( Gordin, FM; Sullam, PM; Wynne, BA, 1994) |
| "The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined." | 5.07 | The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. ( Bartok, AE; Dubé, M; Haghighat, D; Havlir, D; Kemper, CA; Leedom, JM; Sison, JP; Tilles, JG; Yangco, B; Yao, Y, 1994) |
| " The pneumatosis resolved upon treatment of the cryptosporidiosis with paromomycin and clofazimine." | 3.69 | Pneumatosis cystoides intestinalis in AIDS-associated cryptosporidiosis. More than an incidental finding? ( Brown, WR; Samson, VE, 1996) |
| " The following areas were emphasized at the conference: multiresistant gram-positive bacteremias in patients with serious underlying infections, azithromycin's effectiveness against acute community-acquired pneumonia, results of clarithromycin plus ethambutol in HIV-infected patients with MAC bacteremia, duodenal ulcers associated with Helicobacter pylori infections, and use of roxithromycin against AIDS-related cryptosporidium diarrhea." | 3.69 | Macrolides, azalides, and streptogrammins. ( Prescott, LM, 1996) |
| " Results of a Taiwanese trial of thymosin-alpha indicate that it did not help treat Hepatitis B in a statistically significant way." | 3.69 | Pot shots. ( , 1996) |
| " Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose." | 2.87 | Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. ( Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018) |
| "Amikacin was well tolerated." | 2.69 | A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. ( Barber, TW; Currier, J; Ellner, JJ; Hafner, R; Hojczyk, P; Hooton, TM; Jacobs, MR; Limjoco, M; Parenti, DM; Powderly, WG; Simpson, G; van der Horst, C; Williams, PL, 1998) |
| " The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs." | 2.69 | A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Resear ( Chesnut, J; Child, CC; Clotfelter, J; Cohn, DL; El-Sadr, W; Fisher, EJ; Franchino, B; Gibert, CL; Hafner, R; Heifets, L; Hodges, JS; Horsburgh, CR; Korvick, J; Munroe, D; Peng, GT; Ropka, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 30 (90.91) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 2 (6.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nachipo, P | 1 |
| Hermann, D | 1 |
| Quinnan, G | 1 |
| Gordon, MA | 1 |
| Van Voorhis, WC | 1 |
| Iroh Tam, PY | 1 |
| Uthman, MM | 1 |
| Uthman, OA | 1 |
| Yahaya, I | 1 |
| Finet, JF | 1 |
| Similowski, T | 1 |
| Derenne, JP | 1 |
| Le Charpentier, Y | 1 |
| Reddy, MV | 1 |
| Srinivasan, S | 1 |
| Gangadharam, PR | 1 |
| Sullam, PM | 1 |
| Gordin, FM | 1 |
| Wynne, BA | 1 |
| Olliaro, P | 2 |
| Dautzenberg, B | 4 |
| Steven, N | 1 |
| Pithie, A | 1 |
| Wood, M | 1 |
| Innes, J | 1 |
| Kemper, CA | 5 |
| Havlir, D | 2 |
| Haghighat, D | 1 |
| Dubé, M | 1 |
| Bartok, AE | 2 |
| Sison, JP | 3 |
| Yao, Y | 3 |
| Yangco, B | 1 |
| Leedom, JM | 2 |
| Tilles, JG | 2 |
| Kane, C | 1 |
| Camp, B | 1 |
| Lane, N | 1 |
| Deresinski, SC | 3 |
| Saint-Marc, T | 3 |
| Durant, J | 1 |
| Reynes, J | 1 |
| Meyohas, MC | 1 |
| Legrand, MF | 1 |
| Truffot, C | 1 |
| Chauvin, JP | 1 |
| Marneff, E | 1 |
| Touraine, JL | 1 |
| Gordon, SM | 1 |
| Horsburgh, CR | 2 |
| Peloquin, CA | 1 |
| Havlik, JA | 1 |
| Metchock, B | 1 |
| Heifets, L | 2 |
| McGowan, JE | 1 |
| Thompson, SE | 1 |
| Silverman, JF | 1 |
| Holter, JF | 1 |
| Berns, LA | 1 |
| Benning, TL | 1 |
| Neill, JS | 1 |
| Zaugg, M | 1 |
| Salfinger, M | 1 |
| Opravil, M | 2 |
| Lüthy, R | 1 |
| Ravi, S | 1 |
| Holubka, J | 1 |
| Veneri, R | 1 |
| Youn, K | 1 |
| Khatib, R | 1 |
| Hamilton, JR | 2 |
| Brummer, E | 2 |
| Stevens, DA | 2 |
| Shafran, SD | 2 |
| Singer, J | 2 |
| Zarowny, DP | 1 |
| Phillips, P | 1 |
| Salit, I | 2 |
| Walmsley, SL | 1 |
| Fong, IW | 1 |
| Gill, MJ | 1 |
| Rachlis, AR | 1 |
| Lalonde, RG | 1 |
| Fanning, MM | 1 |
| Tsoukas, CM | 2 |
| Ruf, B | 1 |
| Esposito, R | 1 |
| Hoy, JF | 1 |
| Rozenbaum, W | 1 |
| Carosi, GP | 1 |
| Micoud, M | 1 |
| L'Age, M | 1 |
| Pirotta, N | 1 |
| Sassella, D | 1 |
| Samson, VE | 1 |
| Brown, WR | 1 |
| Fattorini, L | 1 |
| Vincent, V | 3 |
| Li, B | 1 |
| Xiao, Y | 1 |
| Varnerot, A | 1 |
| Tortoli, E | 1 |
| Piersimoni, C | 1 |
| Mandler, F | 1 |
| Mascellino, MT | 1 |
| Iona, E | 1 |
| Orefici, G | 1 |
| Chaisson, RE | 1 |
| Keiser, P | 1 |
| Pierce, M | 1 |
| Fessel, WJ | 1 |
| Ruskin, J | 1 |
| Lahart, C | 1 |
| Benson, CA | 1 |
| Meek, K | 1 |
| Siepman, N | 1 |
| Craft, JC | 1 |
| May, T | 1 |
| Brel, F | 1 |
| Beuscart, C | 1 |
| Perronne, C | 1 |
| Doco-Lecompte, T | 1 |
| Grosset, J | 1 |
| Alfandari, S | 1 |
| Chidiac, C | 1 |
| Guery, B | 1 |
| Senneville, E | 1 |
| Mouton, Y | 1 |
| Vinocour, D | 1 |
| Faris, MA | 1 |
| Raasch, RH | 1 |
| Hopfer, RL | 1 |
| Butts, JD | 1 |
| Parenti, DM | 1 |
| Williams, PL | 1 |
| Hafner, R | 2 |
| Jacobs, MR | 1 |
| Hojczyk, P | 1 |
| Hooton, TM | 1 |
| Barber, TW | 1 |
| Simpson, G | 1 |
| van der Horst, C | 1 |
| Currier, J | 1 |
| Powderly, WG | 1 |
| Limjoco, M | 1 |
| Ellner, JJ | 1 |
| Dubé, MP | 1 |
| Torriani, FJ | 1 |
| See, D | 1 |
| Havlir, DV | 1 |
| McCutchan, JA | 1 |
| Sattler, FR | 1 |
| Fournier, S | 1 |
| Burguière, AM | 1 |
| Flahault, A | 1 |
| Treilhou, MP | 1 |
| Eliaszewicz, M | 1 |
| Cohn, DL | 1 |
| Fisher, EJ | 1 |
| Peng, GT | 1 |
| Hodges, JS | 1 |
| Chesnut, J | 1 |
| Child, CC | 1 |
| Franchino, B | 1 |
| Gibert, CL | 1 |
| El-Sadr, W | 1 |
| Korvick, J | 1 |
| Ropka, M | 1 |
| Clotfelter, J | 1 |
| Munroe, D | 1 |
| Thorne, A | 1 |
| Khorasheh, S | 1 |
| Raboud, JM | 1 |
| Wu, AW | 1 |
| Lemieux, C | 1 |
| Cheng, B | 1 |
| Prescott, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis[NCT03341767] | Phase 2 | 33 participants (Actual) | Interventional | 2017-12-14 | Terminated (stopped due to Insufficient accrual rate) | ||
| Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects[NCT00001762] | 532 participants (Actual) | Observational | 1998-02-23 | Completed | |||
| Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection[NCT00001763] | Phase 1 | 15 participants | Interventional | 1998-04-30 | Completed | ||
| A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS[NCT00002331] | 0 participants | Interventional | 1994-01-31 | Completed | |||
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.[NCT00000641] | Phase 2 | 90 participants | Interventional | Completed | |||
| An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS)[NCT00001047] | Phase 3 | 400 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for clofazimine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Child; Clarithrom | 2013 |
Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clofazim | 1993 |
Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals.
Topics: 4-Quinolones; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 1998 |
18 trials available for clofazimine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antiprotozoal | 2018 |
Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; | 1994 |
Control of the body burden of M. avium complex is associated with improved quality of life and prolonged survival of patients with AIDS: a prospective trial with rifabutin combined with isoniazid, clofazimine, ethambutol.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Body Burden; Clofazimine; Drug Therapy, Combinat | 1994 |
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; Ethambutol; Femal | 1994 |
Transient bacteremia due to Mycobacterium avium complex in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; Drug Therapy, Combination; Et | 1994 |
[Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection].
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agen | 1994 |
[Mycobacterium avium intracellulare infections. Treatment with a clarithromycin-clofazimine combination. 18 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Chemical and Drug | 1993 |
Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Bacteremi | 1996 |
Treatment of Myocardium avium complex infection: does the beige mouse model predict therapeutic outcome in humans?
Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; Clofazimine; Colony Count, Mi | 1996 |
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Bacterem | 1996 |
Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Inflammatory | 1996 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clarithromycin; Clofazimine; Drug Therapy, | 1997 |
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Bacteremia; Ciprofloxacin; Clofazimine; Colo | 1998 |
Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
Topics: AIDS-Related Opportunistic Infections; Bacteremia; Ciprofloxacin; Clarithromycin; Clofazimine; Drug | 1999 |
Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients.
Topics: Aged; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents, Non-Steroidal; Bacteremia; Cl | 1999 |
A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Resear
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cl | 1999 |
Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Canada; | 2000 |
12 other studies available for clofazimine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
[Reversible pulmonary overload with clofazimine (Lamprene) in HIV-positive subjects].
Topics: AIDS-Related Opportunistic Infections; Bronchoalveolar Lavage Fluid; Clofazimine; HIV Seropositivity | 1995 |
In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC).
Topics: AIDS-Related Opportunistic Infections; Animals; Clofazimine; Colony Count, Microbial; Dose-Response | 1994 |
Corticosteroid therapy for AIDS patients with Mycobacterium avium-intracellulare infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Azithromycin; Ciprofloxacin; Clofazimine; Drug Therapy | 1994 |
Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.
Topics: Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agent | 1993 |
Negative images due to clofazimine crystals simulating MAI infection in a bronchoalveolar lavage specimen.
Topics: Adult; AIDS-Related Opportunistic Infections; Bronchoalveolar Lavage Fluid; Clofazimine; Crystalliza | 1993 |
Clofazimine-induced eosinophilic gastroenteritis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clofazimine; Eosin | 1993 |
Pneumatosis cystoides intestinalis in AIDS-associated cryptosporidiosis. More than an incidental finding?
Topics: Adult; AIDS-Related Opportunistic Infections; Clofazimine; Cryptosporidiosis; Humans; Male; Paromomy | 1996 |
Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agen | 1996 |
Pulmonary clofazimine crystals in two patients with the acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Bronchoalveolar Lav | 1997 |
Advances in prevention and treatment of MAC.
Topics: AIDS-Related Opportunistic Infections; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Clinical | 1995 |
Macrolides, azalides, and streptogrammins.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 1996 |
Pot shots.
Topics: Acetylcysteine; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercula | 1996 |